title: Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors.
abstract: Tyrphostins are a group of low molecular weight synthetic inhibitors of protein tyrosine kinases (PTK). The intracellular domains of the receptors for epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha), insulin-like growth factor 1 (IGF-1) possess PTK activity. Since EGF, TGF-alpha and IGF-1 are considered to play an important role in the proliferation of pancreatic cancer cells, we studied the effects of tyrphostins on the growth of three human pancreatic cancer cell lines (MiaPaCa-2, Panc-1 and CAV). The tyrphostins AG17, T23 and T47 all inhibited EGF and serum-stimulated DNA synthesis. AG17 was found to be the most potent of these agents and caused a dose-dependent but reversible inhibition of cell growth. Furthermore using an immunoblotting procedure we also found AG17 to inhibit EGF-induced tyrosine phosphorylation in the MiaPaCa-2 cell line. Tyrosine kinase inhibitors may prove to be useful agents for the treatment of pancreatic cancer.
authors.affiliation: Academic Surgical Unit, St. Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London, UK.
authors.forename: J
authors.initials: J
authors.lastname: Gillespie
authors.forename: J F
authors.initials: JF
authors.lastname: Dye
authors.forename: M
authors.initials: M
authors.lastname: Schachter
authors.forename: P J
authors.initials: PJ
authors.lastname: Guillou
mesh_terms: D002396:Catechols / Q000494:pharmacology / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D006801:Humans; D015151:Immunoblotting; D009570:Nitriles / Q000494:pharmacology / Q000627:therapeutic use; D010183:Pancreatic Ducts; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D010636:Phenols / Q000494:pharmacology / Q000627:therapeutic use; D010766:Phosphorylation / Q000187:drug effects; D010982:Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000201:enzymology; D014443:Tyrosine / Q000378:metabolism; D020032:Tyrphostins
chemical_list: D002396:Catechols; D004273:DNA, Neoplasm; D009570:Nitriles; D010636:Phenols; D010982:Platelet-Derived Growth Factor; D020032:Tyrphostins; C060152:tyrphostin 47; D014443:Tyrosine; C001784:SF 6847; D004815:Epidermal Growth Factor; D011505:Protein-Tyrosine Kinases; C060641:tyrphostin A23